Neurotoxic effect in lactating mice pups received oseltamivir phosphate (tamiflu) through milk from dosed nursing mothers during lactation period
Article Sidebar
Main Article Content
Abstract
The present study was aimed to evaluate neurotoxic effects of oseltamivir phosphate in lactating pups of orally dosed mice mothers during lactation. Twelve recently parturited female albino mice were divided equally into three groups, one control and two treated groups, each group consists of 4 dosed dams and 8 chosen pups .The nursing dams of T1 and T2 dosed daily orally with 1mg/kg and 5mg/kg,oseltamivir phosphate respectively representing the therapeutic dose and 5 fold dose of drug while control group dosed with distilled water. Lactating mice pups of all groups examined for the following parameters: First parameter was body weight changes and gain: In which T1group showed significant increase in mice pups body weight gain after 14 day of treatment in comparison with control group and T2. Second parameter was clinical symptoms observation /daily, all treatment groups that showed neurotoxic symptoms appeared from 1st dose and extended along the next few days of treatment to be gradually disappeared and completely lost within the last days of treatment in dose dependent manner.These neurotoxic symptoms were weakness, convulsions ,lay on back or side, extended body, incoordination ,extended limbs and limbs stiffness. Third parameter was gross and histopathological studies which demonstrate that the brain was the most affected organ beside extensive lesions in liver, kidney, stomach and small intestine of treated groups in dose dependent manner.
In conclusion of this study revealed that Oseltamivir phosphate produce neurotoxic effect in mice pups through indirect administration by nursing mothers dosing during lactation period and the level of toxicity was in dose dependent manner.
Downloads
Article Details
How to Cite
References
He, G.; Massarella, J. and Ward, P. (1999). Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet., 37:471-484.
Moscona, A. (2005). Neuraminidase inhibitors for influenza. N. Engl. J. Med.,353:1363–1373.
Whitley, RJ.; Hayden, FG.; Reisinger, KS.; Young, N.; Dutkowski, R. Ipe, D.; Mills, RG. and Ward, P. (2001). Oral oseltamivir treatment of influenza in children. Pediatr Infect. Dis. J., 20: 127–133.
Hayden, FG.; Belshe, R.; Villanueva, C.; Lanno, R.; Hughes, C.; Small, I.; Dutkowski, R.; Ward, P. and Carr, J. (2004). Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J. Infect. Dis., 189:440–449
Toovey, S.; Rayner, CR.; Prinssen, E.; Chu, T. ; Donner, B.; Dutkowski, R.; Sacks, S.; Solsky, J.; Small, I. and Reddy, D. (2008). Post-marketing safety assessment of neuropsychiatric adverse event risk in patients with influenza treated with oseltamivir. Abstr. X Int. Symp. Respir Viral Infect Singapore City,Singapore
Fukumoto, Y.; Okumura, A.; Hayakawa, F.; Suzuki, M.; Kato, T.; Watanabe, K. and Morishima, T. (2007). Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. Brain Dev- 29:425–430.
Lin, CH.; Huang, YC.; Chiu, CH.; Huang, CG.; Tsao, KC. and Lin, TY. (2006). Neurologic manifestations in children with influenza B virus infection. Pediatr. Infect.
Dis. J., 25:1081–1083.
Hafez, ES.(1970).Reproductive and breeding. Techniques For Laboratory animals .Lea and ibiges,philadilphia.
Luna, LG. (1989).Manuual of Histopathology Staining Methods of Armed Forces Institute of Pathology ,3rd ed.McGraw Hill Book Co., New Yorh, pp:7-9
Snedecor, GW. and Cochran, WG. (1973). Statistical Methods. 6th the Iowa state University press., Pp:238-248.
Kobayashi, K.(2001). Role of Catecholamine Signaling in Brain and Nervous System Functions: New Insights from Mouse Molecular Genetic Study .Journal of Investigative Dermatology Symposium Proceedings, 6: 115–121.
Smith, GP. and Schneider. LH. ( 1998). Relationship between mesolimbic dopamine function and eating behavior .Ann. NY. Acad. Sci., 537:254-261
Ribatti, D.; Nico, B.; Crivellato, E. and Artico, M. (2006). Development of the bloodbrain barrier: a historical point of view. Anat. Rec.B. New Anat., 289: 3–8.
Wooltorton, E. ( 2004). Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ., 170: 336.
Chugai Pharm Co( 2002). New drug approval package (NAP) of oseltamivir (in Japanese) ; Tamiflu capsule for treatment.
Yoshino,T.; Nisijima, K.; Shioda, K.; Yui, K. and.Kato, S. (2008).oseltamivir(tamiflu)increase dopamine level in rat. Neurscince,letter, 438: 56-69.
Gilman, S.(1992). Cerebellum and Motor Dysfunction. Chapter 23. In Asbury, AK, McKhann, GM, and McDonald, WI (eds): Diseases ofNervous tem: Clinical Neurobiology, 2nd ed. WB Saunders,jPhiladelphia.
Dow, R.; Kramer, R. and Robertson, L. (1991). Disorders of the Cerebellum. Chapter 37. In joynt R J (ed): Clinical Neurology, J B Lippincott, Philadelphia -vol 3.
Thompson, PD. and Day, BL. (1993): The Anatomy and Physiology of Cerebellar Disease. Adv. Neurol ., 61:15 .
Kimberlin D W Shalabi M Abzug M J Lang D Jacobs R F Storch G Bradley J S Wade K C Ramilo O Romero J R Shelton M Leach C Guzman-Cottrill J Robinson J Abughali N Englund J Griffin J Jester P Cloud Gretchen A Whitley R J and the NIAID Collaborative Antiviral Study Group.(2010). Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age.Pediatric Infectious Disease Journal: March 2010 - Volume 29 - Issue 3 – pp: 195-198